The proportion of patients reaching secondary endpoint ( HbA1c < 54 mmol/mol without hypoglycemic event or weight gain 3 % with baseline glycated hemoglobin > 54 mmol/mol was higher for vildagliptin 45.7 % vs 31.4 % in the control arm , odds ratio 1.84 ( 1.26 , 2.68 ) , p < 0.001 .